A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors
← catalyst calendarSponsored by Beyond Air Inc. (industry) · XAIR — their whole pipeline →.
Phase
Phase 1
Status
Unknown status
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
38estimated
Sites
4
Country
Israel
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-08-14 | actual | When the study began enrolling |
| Primary completion | 2025-05-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2022-04-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-08-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cancer
Interventions
- Drug: Nitric Oxide 25,000 ppm — also filed as gNO injection
- Drug: Nitric Oxide 50,000 ppm
- Drug: Nitric Oxide 100,000 ppm
- Drug: Nitric Oxide selected dose
Primary outcome
what the primary-completion date above is the date OFIncidence of AEs, SAEs and DLTs (safety) parameters.
measured up to12 weeks from injection
Permalink · XAIR's whole pipeline · Catalyst calendar · Every registered study · What changed